Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple biomarkers

Journal of Exposure Science and Environmental Epidemiology

Volumn 19, Issue 3, 2009, Pages 284-297

  Mosquin, Paul L ^a   Licata, Amy Collins ^a   Liu, Bing ^a   Sumner, Susan C J ^a   Okino, Miles S ^b  

^a RTI INTERNATIONAL   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Biomarkers; Exposure reconstruction; PBPK model

Indexed keywords

BIOLOGICAL MARKERS; CHLORPYRIFOS; HUMANS; INSECTICIDES; LIKELIHOOD FUNCTIONS; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS;

EID: 60349091161     PISSN: 15590631     EISSN: 1559064X     Source Type: Journal    
DOI: 10.1038/jes.2008.17     Document Type: Article

References (39)

1. Andersen M.E., Clewell III H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 1987: 87(2): 185-205.
2. Barr D.B., Allen R., Olsson A.O., Bravo R., Caltabiano L.M., and Montesano A., et al. Concentrations of selective metabolites of organophosphorus pesticides in the United States population. Environ Res 2005: 99(3): 314-326.
3. Barr D.B., Bravo R., Weerasekera G., Caltabiano L.M., Whitehead R.D., and Olsson A.O., et al. Concentrations of dialkyl phosphate metabolites of organophosphorous pesticides in the U.S. population. Environ Health Perspect 2004: 112(2): 186-200.
4. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997: 13: 407-484.
5. Clewell H.J., Gearhart J.M., Gentry P.R., Covington T.R., VanLandingham C.B., Crump K.S., and Shipp A.M. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 1999: 19(4): 547-558.
6. Dow AgroSciences. Chlorpyrifos - North America 2007: http://www.dowagro.com/chlorp/na/about/.
7. Dow Chemical Co. Simusolv - Modeling and Simulation Software. Dow Chemical Co., Midland, MI, 1990.
8. Egeghy P.P., Quackenboss J.J., Catlin S., and Ryan P.B. Determinants of temporal variability in NHEXAS-Maryland environmental concentrations, exposures, and biomarkers. J Expo Anal Environ Epidemiol 2005: 15(5): 388-397.
9. Furlong C.E., Richter R.J., Seidel L., Costa G., and Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989: 180: 242-247.
10. Garfitt S.J., Jones K., Mason H.J., and Cocker J. Exposure to the organophosphate diazinon: data from a human volunteer study with oral and dermal doses. Toxicol Lett 2002: 134(1-3): 105-113.
11. Gearhart J.M., Jepson G.W., Clewell III H.J., Andersen M.E., and Conolly R.B. Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol Appl Pharmacol 1990: 106: 295-310.
12. Gelman A., Bois F.Y., and Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 1996: 91: 1400-1412.
13. Georgopoulos P., Roy A., and Gallo M.A. Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models. J Expo Anal Environ Epidemiol 1994: 4(3): 309-328.
14. Griffin P., Mason H., Heywood K., and Cocker J. Oral and dermal absorption of chlorpyrifos: a human volunteer study. Occup Environ Med 1999: 56: 10-13.
15. Hayes A.W. Principles and Methods of Toxicology, 4th edn. Raven Press, New York, 2001.
16. Henderson R.F. Strategies for the use of biomarkers of exposure. Toxicol Lett 1995: 82/83: 379-383.
17. Klaassen C.D. Casarett and Doull's Toxicology: the Basic Science of Poisons, 6th edn. McGraw-Hill, New York, 2001.
18. McKone T.E. Linking a PBPK model for chloroform with measured breath concentrations in showers: implications for dermal exposure models. J Expo Anal Environ Epidemiol 1993: 3: 339-365.
19. Morgan M.K., Sheldon L.S., Croghan C.W., Jones P.A., Robertson G.L., and Chuang J.C., et al. Exposures of preschool children to chlorpyrifos and its degradation product 3,5,6-trichloro-2-pyridinol in their everyday environments. J Expo Anal Environ Epidemiol 2005: 15: 297-309.
20. Nash R.G., Kearney P.C., Maitlen J.C., Sell C.R., and Fertig S.N. Agricultural applicators exposure to 2,4-dichlorophenoxyacetic acid. ACS Symp Ser 1982: 182: 119-132.
21. National Research Council. Human Biomonitoring for Environmental Chemicals. The National Academies Press, Washington DC, 2006.
22. Needham L.L., Ashley D.L., and Patterson D.G. Case studies of the use of biomarkers to assess exposures. Toxicol Lett 1995: 82/83: 373-378.
23. Nolan R.L., Rick D.L., Freshour N.L., and Saunders J.H. Chlorpyrifos: pharmacokinetics in human volunteers.Toxicol Appl Pharmacol 1984: 73: 8-15.
24. Pang Y., MacIntosh D.L., Camann D.E., and Ryan P.B. Analysis of Aggregate exposure to chlorpyrifos in the NHEXAS-Maryland investigation. Environ Health Persp 2002: 110: 235-240.
25. Ramsey J.C., and Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene monomer in rats and humans. Toxicol Appl Pharmacol 1984: 73: 159-175.
26. Reddy M., Yang R.S., Andersen M.E., and Clewell H.J. Physiologically Based Pharmacokinetic Modeling: Science and Applications. John Wiley & Sons Inc, Hoboken, NJ, 2005.
27. Rigas M.L., Okino M.S., and Quackenboss J.J. Use of a pharmacokinetic model to assess chlorpyrifosexposure and dose in children based on urinary biomarker measurements. Toxicol Sci 2001: 61: 374-381.
28. Roy A., and Georgopoulos P.G. Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models. J Expo Anal Environ Epidemiol 1998: 8(3): 407-422.
29. Sams C., Cocker J., and Lennard M.S. Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 2004: 34: 861-873.
30. Sohn M.D., McKone T.E., and Blancato J.N. Reconstructing population exposures from dose biomarkers: inhalation of trichloroethylene (TCE) as a case study. J Expo Anal Environ Epidemiol 2004: 14: 204-213.
31. Sultatos L.G. Mammalian toxicology of organophosphorus pesticides. J Toxicol Environ Health 1994: 43: 271-289.
32. Tan Y.M., Liao K.H., and Clewell H.J. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol 2007: 17: 591-603.
33. Tan Y.M., Liao K.H., Conolly R.B., Blount B.C., Mason A.M., and Clewell H.J. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A 2006: 69(18): 1727-1756.
34. Timchalk C., Kousba A., and Poet T.S. Monte Carlo analysis of the human chlorpyrifos-oxonase(PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol Lett 2002a: 135: 51-59.
35. Timchalk C., Nolan R.J., Mendrala D.A., Dittenber D.A., Brzak K.A., and Mattson J.L. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci 2002b: 66: 34-53.
36. USDHHS. Toxicological Profile for Chlorpyrifos. US Dept. of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry: Atlanta, GA, USA, 1997.
37. Wakefield J. The Bayesian analysis of population pharmacokinetic models. J Am Stat Assoc 1996: 91(433): 62-75.
38. Wallace L., Pellizari E., and Gordon S. A linear model relating breath concentrations to environmental exposures: application to a chamber study of four volunteers exposed to volatile organic chemicals. J Expo Anal Environ Epidemiol 1993: 3: 75-102.
39. Wilson N.K., Chuang J.C., Lyu C., Menton R., and Morgan M.K. Aggregate exposures of nine preschool children to persistent organic pollutants at day care and at home. J Expo Anal Environ Epidemiol 2003: 13: 187-202.